CPT 81465: Mitochondrial Genome Deletion Analysis
Commercial payers pay $977 on average nationally for this procedure.
CPT code 81465 describes a genomic sequence analysis panel that evaluates the entire mitochondrial genome for large deletions associated with neuromuscular and mitochondrial disorders; the service is a mitochondrial genome deletion analysis (including heteroplasmy detection when performed) typically provided as a laboratory molecular diagnostic test in a clinical molecular genetics or specialized laboratory setting, often processed from blood or tissue specimens.
Customize your policy alerts
Sign up for cpt 81465 policy alerts
Get alerted when payer policies referencing 81465 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
BUCA’s national average commercial rate for CPT 81465 sits at $976.90, serving as a useful midpoint for comparing commercial payers. Blue Cross Blue Shield shows the highest overall spread with a P75–P25 range of $338.40 ($1,104.30 − $766.60), reflecting notable regional or contract variability. Cigna’s spread is $733.60 ($1,212.40 − $478.80), the widest among listed commercial payers, while UnitedHealth Group is comparatively tight with a spread of $542.90 ($936.00 − $393.10).
Aetna’s interquartile spread is $575.00 ($1,150.00 − $572.50), indicating moderate dispersion around BUCA’s average. Blue Cross Blue Shield and Cigna show the largest IQR-driven variability, suggesting greater upside and downside potential versus BUCA, while UnitedHealth Group and Aetna are comparatively more clustered around their medians and means.